Early Access — free while we kick the tires
EdgarHawk

Kolean Chad J

Chief Financial Officer

Officer
1 filing analyzed · 1 company · Latest 2025-07-03

Companies

Company Buys Sells Direction
Cellectar Biosciences, Inc. CLRB 1 0 Net buying

Activity

July 2025
high
Buy
5,000 shares
$24,950
Significance 7/10

CFO Kolean Chad J bought 5,000 CLRB shares at $4.99 as part of cluster buy; stock down 94.7% from $90.60 high, company unprofitable with $-6.6M net income

Kolean Chad J, Chief Financial Officer, purchased 5,000 shares at $4.99 on 2025-07-02, increasing his holdings from 1,418 to 6,418 shares (+352.6%). This transaction is part of a cluster buy pattern with 2 other insiders purchasing within the past 14 days, indicating coordinated insider acquisition activity. The stock has declined 94.7% from its 52-week high of $90.60 to the current price of $4.80, and the company reported full-year net income of $-6,604,029.00, demonstrating material unprofitability. The CFO's purchase at this depressed price level, combined with simultaneous buying by other insiders, warrants investor scrutiny of whether this reflects management's assessment of fundamental value or broader market concerns about the company's trajectory.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access